Dar Al-Shifa Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Dar Al-Shifa Pharmaceuticals has been growing earnings at an average annual rate of 86.9%, while the Pharmaceuticals industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 33.6% per year. Dar Al-Shifa Pharmaceuticals's return on equity is 17.9%, and it has net margins of 15.8%.
Key information
86.9%
Earnings growth rate
86.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 33.6% |
| Return on equity | 17.9% |
| Net Margin | 15.8% |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Dar Al-Shifa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 31 | 5 | 6 | 0 |
| 30 Sep 21 | 27 | 5 | 5 | 0 |
| 31 Dec 20 | 23 | 3 | 5 | 0 |
| 30 Jun 20 | 17 | 1 | 4 | 0 |
| 31 Mar 20 | 19 | 2 | 4 | 0 |
| 31 Dec 19 | 23 | -1 | 5 | 1 |
| 31 Dec 18 | 18 | 3 | 4 | 0 |
| 31 Dec 17 | 17 | 2 | 4 | 0 |
| 31 Dec 16 | 19 | 1 | 7 | 0 |
Quality Earnings: PHARMACARE has high quality earnings.
Growing Profit Margin: PHARMACARE's current net profit margins (15.8%) are higher than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PHARMACARE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare PHARMACARE's past year earnings growth to its 5-year average.
Earnings vs Industry: PHARMACARE earnings growth over the past year (86.9%) exceeded the Pharmaceuticals industry 9.9%.
Return on Equity
High ROE: PHARMACARE's Return on Equity (17.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/18 13:07 |
| End of Day Share Price | 2022/12/19 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dar Al-Shifa Pharmaceuticals Company is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|